Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

Editas Medicine Inc. (NASDAQ:EDIT) disclosed in an SEC filing that Judith Abrams resigned as CMO. The gene editing company did not immediately respond to a request for comment on its succession plans for the post.

Immunocore Ltd. hired Brian Di Donato as CFO and head of strategy. He succeeds Paul Fry, who stepped down as CFO in 2018. Donato was SVP and CFO of Achillion Pharmaceuticals Inc. Immunocore raised $130 million in March for its pipeline of TCR bispecifics (see “Immunocore’s $130M series B”)...